Clinical Trials Logo

Vitiligo clinical trials

View clinical trials related to Vitiligo.

Filter by:

NCT ID: NCT03741738 Completed - Vitiligo Clinical Trials

The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity

Start date: August 30, 2018
Phase:
Study type: Observational

Vitiligo is an acquired depigmented disorder that causes white spots on the skin due to the loss of melanocytes. It is a common disease which accounts for 0.5-1% of the whole population. It is a refractory skin disease with 25-50 thousand patients in Korea. And it is often caused in the exposed areas of the patient, causing a great deal of mental and social dysfunction in the patient's life, and may lead to suicide attempts.

NCT ID: NCT03718962 Completed - Clinical trials for Brief Description of Focus of Study Instead

The Effect of UVB Phototherapy With Microneedling and Circled Needing in Vitiligo Patients

Start date: October 30, 2018
Phase: N/A
Study type: Interventional

Vitiligo is a relatively common acquired disorder of pigmentation characterized by the development of well-defined white macules on the skin. Biopsies of lesional skin reveal a loss of epidermal melanocytes. Lesions may occur in a localized or generalized distribution and may coalesce into large, depigmented areas. Given the contrast between the white areas and normal skin, the disease is most disfiguring in darker skin types and has a profound impact on the quality of life of both children and adults . Patients with vitiligo often experience stigmatization, social isolation, and low self-esteem. The therapys include topical steroids, topical immunosuppresant, systemic steroids, phototherapy, and surgery. The aim of this study is to investigate the effect of phototherpy and accupuncture combined therapy for vitiligo patients.

NCT ID: NCT03715829 Completed - Clinical trials for Active Non-segmental Vitiligo

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.

NCT ID: NCT03622320 Completed - Metabolic Syndrome Clinical Trials

Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo

Start date: July 1, 2018
Phase:
Study type: Observational

This study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.

NCT ID: NCT03608917 Completed - Vitiligo Clinical Trials

Efficacy and Safety of Total Glucosides of Paeony Combined With NB-UVB on Treating Vitiligo

Start date: April 17, 2018
Phase: N/A
Study type: Interventional

1. Total Glucosides of Paeony(TGP) As a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony(TGP). Paeoniflorin accounted for more than 90% of the TGP, is the main active ingredient of white peony root.By pharmacological and clinical studies of TGP, it have found that the mechanism of TGP is unique and mainly acts on the upstream of the immune response - inhibiting the presentation of antigens. It is different from immunosuppressive agents on T, B lymphocytes, or hormones and other drugs acting on the whole process. 2. Vitiligo Vitiligo is a pigment deprived skin disease caused by the destruction of melanocytes, the global incidence of about 1%. The pathogenesis is not yet clear, the current study shows that oxidative stress and autoimmunity is an important part of its occurrence and development. 3. The basic and clinical research of TGP used in vitiligo The ratio of cluster of differentiation 4+ / cluster designation 8+ T cell vs. cluster of differentiation 4+ chronotropic dose 25+ in the peripheral blood of patients with vitiligo could be significantly increase, after patients treatment by TGP combined with tacrolimus. Thereby enhancing the patient's maintenance of immune self-stability and Immune tolerance ability, promoting the healing of skin lesions. It showed significant effect in stable vitiligo,when patients treated by autologous epidermal grafting combined with TGP.

NCT ID: NCT03535051 Completed - Stable Vitiligo Clinical Trials

Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The aim the clinical trial was to find out whether fractional CO₂ laser sessions in combination with application of daily topical tacrolimus 0.03% would enhance the action of the drug and pose as a possible combination treatment option for stable vitiligo lesions. This combination treatment was applied to one side of the body and the response was compared to the response of the lesions on the other side of the body to daily topical tacrolimus 0.03% alone, which was used as control.

NCT ID: NCT03468855 Completed - Vitiligo Clinical Trials

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Start date: March 19, 2018
Phase: Phase 2
Study type: Interventional

The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.

NCT ID: NCT03411135 Completed - Vitiligo Clinical Trials

Vitiligo Extent Score (VES) Score in Comparison to Vitiligo Area and Severity Index (VASI) Score

Start date: April 2016
Phase: N/A
Study type: Observational

All patients with vitiligo attending dermatology outpatient clinic at Kasr Alainy Teaching Hospital will be enrolled in this study to compare VES and VASI scores and evaluate them as assessment methods

NCT ID: NCT03402633 Completed - Leucotrichia Clinical Trials

Leucotrichia in Vitiligo

Start date: April 2016
Phase: N/A
Study type: Observational

The incidence of leucotrichia has been reported to range from 9 to 48.4% of all vitiligo patients.Leucotrichia is more often observed in segmental vitiligo with a very high percentage. However, further studies considering the prevalence of leucotrichia in different types of vitiligo need to be conducted.

NCT ID: NCT03378011 Completed - Acral Vitiligo Clinical Trials

UVA1 Phototherapy in Acral Vitiligo

Start date: November 2015
Phase: N/A
Study type: Interventional

evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.